cardio:arrhythmias:atropine
Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
| cardio:arrhythmias:atropine [2026/02/13 17:14] – created andrew2393cns | cardio:arrhythmias:atropine [2026/02/13 17:16] (current) – andrew2393cns | ||
|---|---|---|---|
| Line 3: | Line 3: | ||
| <WRAP right 300px> | <WRAP right 300px> | ||
| <WRAP infobox> | <WRAP infobox> | ||
| - | ^ Drug Overview | | + | ^ Drug Overview |
| - | | Class | [[cardio: | + | | Drug Class | [[cardio: |
| | Subclass | Competitive Muscarinic Antagonist | | | Subclass | Competitive Muscarinic Antagonist | | ||
| - | | Primary CV Use | Symptomatic Bradycardia | | + | | Primary CV Use | [[cardio: |
| - | | Route | IV / IM / SQ / Ophthalmic | | + | | Route | IV / IM / SQ / [[ophthalmology: |
| | Onset (IV) | 1–2 minutes | | | Onset (IV) | 1–2 minutes | | ||
| | Duration | 30–60 minutes | | | Duration | 30–60 minutes | | ||
| Line 18: | Line 18: | ||
| | Black Box Warning | No | | | Black Box Warning | No | | ||
| | Controlled | No | | | Controlled | No | | ||
| - | | FDA Approval | 1939 | | ||
| </ | </ | ||
| </ | </ | ||
| Line 26: | Line 25: | ||
| Atropine is a competitive antagonist of muscarinic acetylcholine receptors. | Atropine is a competitive antagonist of muscarinic acetylcholine receptors. | ||
| - | In cardiovascular practice, it is used to treat symptomatic bradycardia by blocking parasympathetic (vagal) tone at the SA and AV nodes. | + | In cardiovascular practice, it is used to treat [[cardio: |
| It increases heart rate by removing inhibitory cholinergic signaling. | It increases heart rate by removing inhibitory cholinergic signaling. | ||
| Line 37: | Line 36: | ||
| Primary Target: | Primary Target: | ||
| - | * M2 muscarinic receptors in the SA and AV nodes | + | * M2 muscarinic receptors in the SA and AV nodes (see [[cardio: |
| Normal Physiology: | Normal Physiology: | ||
| Line 50: | Line 49: | ||
| Net Effect: | Net Effect: | ||
| - | * Increased heart rate | + | * ↑ Heart rate |
| * Improved AV conduction | * Improved AV conduction | ||
| Line 58: | Line 57: | ||
| Cardiovascular: | Cardiovascular: | ||
| - | * Symptomatic sinus bradycardia | + | * [[cardio: |
| - | * AV nodal block (vagal-mediated) | + | * [[cardio: |
| - | Advanced Cardiac Life Support (ACLS): | + | ACLS: |
| - | * First-line for unstable bradycardia | + | * First-line |
| Other Uses: | Other Uses: | ||
| - | * Organophosphate poisoning | + | * [[toxicology: |
| - | * Pre-anesthetic | + | * Pre-anesthetic |
| - | * Ophthalmic | + | * [[ophthalmology: |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 82: | Line 81: | ||
| * Doses < 0.5 mg may paradoxically worsen bradycardia | * Doses < 0.5 mg may paradoxically worsen bradycardia | ||
| - | Pediatric dosing differs — weight-based. | + | If ineffective: |
| + | * Proceed to [[cardio: | ||
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 89: | Line 89: | ||
| Absolute: | Absolute: | ||
| - | * None in emergent bradycardia | + | * None in emergent |
| - | Relative: | + | Relative |
| - | * Glaucoma | + | * [[ophthalmology: |
| - | * Severe tachyarrhythmias | + | * Severe tachyarrhythmias |
| * Obstructive uropathy | * Obstructive uropathy | ||
| * Ileus | * Ileus | ||
| Line 101: | Line 101: | ||
| ===== Adverse Effects ===== | ===== Adverse Effects ===== | ||
| - | Common (Anticholinergic | + | Common (anticholinergic |
| * Tachycardia | * Tachycardia | ||
| * Dry mouth | * Dry mouth | ||
| Line 113: | Line 112: | ||
| * Arrhythmias | * Arrhythmias | ||
| * Hyperthermia (impaired sweating) | * Hyperthermia (impaired sweating) | ||
| + | |||
| + | Mechanism-based: | ||
| + | * “Hot as a hare, dry as a bone, blind as a bat, mad as a hatter” | ||
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 119: | Line 121: | ||
| Additive anticholinergic effects with: | Additive anticholinergic effects with: | ||
| + | * [[cardio: | ||
| + | * [[psych: | ||
| + | * [[psych: | ||
| + | * [[allergy: | ||
| - | | + | Bradycardia context / AV node: |
| - | * Antihistamines | + | * Use caution if combined with AV nodal blockers: |
| - | * TCAs | + | |
| - | * Antipsychotics | + | * [[cardio:ccb: |
| - | + | * [[cardio: | |
| - | Use caution with: | + | |
| - | * AV nodal blocking agents | + | |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 136: | Line 140: | ||
| * Blood pressure | * Blood pressure | ||
| * Mental status (elderly) | * Mental status (elderly) | ||
| + | * Signs of anticholinergic toxicity | ||
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 141: | Line 146: | ||
| ===== Clinical Pearls ===== | ===== Clinical Pearls ===== | ||
| - | * Removes | + | * Atropine removes |
| - | * Ineffective in Mobitz II or complete heart block distal to AV node | + | * Ineffective in infranodal block (e.g., [[cardio: |
| - | * Avoid low doses (< 0.5 mg IV) | + | * Avoid low doses (< 0.5 mg IV) due to paradoxical |
| - | * First-line ACLS drug for unstable | + | * If no response, escalate quickly to [[cardio: |
| - | * Consider | + | |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 151: | Line 155: | ||
| ===== Comparison Within Arrhythmia Management ===== | ===== Comparison Within Arrhythmia Management ===== | ||
| - | Compared | + | Opposite AV nodal effects compared |
| - | * [[cardio: | + | * [[cardio: |
| - | * [[cardio: | + | * [[cardio: |
| + | * [[cardio: | ||
| Atropine: | Atropine: | ||
| - | * Blocks parasympathetic tone | + | * ↑ SA node rate |
| - | * Increases heart rate | + | * ↑ AV conduction |
| - | * Short-acting | + | * Used for bradycardia, not tachyarrhythmias |
| - | * Used in bradycardia | + | |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 166: | Line 170: | ||
| * [[cardio: | * [[cardio: | ||
| + | * [[cardio: | ||
| * [[cardio: | * [[cardio: | ||
| * [[cardio: | * [[cardio: | ||
| + | * [[cardio: | ||
| * [[cardio: | * [[cardio: | ||
cardio/arrhythmias/atropine.1771002861.txt.gz · Last modified: by andrew2393cns
